Replies to post #8282 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Nothing has changed in the clinicaltrials.gov description of the DIC trial since it was first posted in July 2007.

>"ClinicalTrials.gov processed this record on February 21, 2008"<

This is the date of your inquiry—nothing more. Regards, Dew

[DewDiligence]

Semantic nitpicking:

>…there does seem to be a dose-ranging aspect to the trial.<

Three doses of ATryn are being tested but I would not characterize this study as dose-ranging, a term generally used for phase-1 trials where the maximum dose has not yet been established. Dose finding, as opposed to dose ranging, means that a goal of the study is to pick the best dose(s) to take into phase-3.